Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial

BACKGROUND: A previous phase IV trial revealed sex as a potential effect modifier of MUSKARDIA efficacy in stable coronary artery disease (CAD). OBJECTIVE: To assess the clinical effect of MUSKARDIA as a supplemental treatment to optimal medical therapy (OMT) in stable CAD cases. METHODS: This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Haiming, Zhou, Jingmin, Ma, Changsheng, Ji, Fusui, Wu, Yang, Zhao, Yulan, Qian, Jun, Wang, Xiaolong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651060/
https://www.ncbi.nlm.nih.gov/pubmed/36386372
http://dx.doi.org/10.3389/fcvm.2022.1002400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651060/
https://www.ncbi.nlm.nih.gov/pubmed/36386372
http://dx.doi.org/10.3389/fcvm.2022.1002400

Ejemplares similares